tyb
Elon Musk N628TS G6 on ground at Hawthorne, Ca from Brownsville, TX
guess he is not going to be at launch tomorrow unless he does a red-eye or his jet was just moved without him-doubt that.
How to watch live as SpaceX launches NASA astronauts to the ISS Wednesday
If weather cooperates, a Falcon 9 rocket is scheduled to carry two astronauts from US soil to the space station on May 27. The last time the US launched astronauts from within its borders was 2011.
https://www.cnet.com/how-to/how-to-watch-live-as-spacex-launches-two-nasa-astronauts-to-the-iss-wednesday/
HOOVR02 USAF TC-135W Stratolifter and SNOOP03 USAF TC-135S Cobra Ball heading back to Offutt AFB from Travis AFB-thses went in to Travis Saturday as part of a larger convoy of Rivet Joints and an Open Skies AC
SAM764 USAF G5 from JBA sw
CNV4744 US Navy Clipper east from Lemoore NAS, CA
CNV4441 US Navy Clipper ne from Pensacola NAS, FL
muh fee-fees
CHUFF67 E-6B Mercury off western Florida and ne now-out of Tinker AFB
Calithera Biosciences sold by Biotechnology Value Partners LP: $13.70m-May 21
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors. Number of employees : 93 people.
https://www.marketscreener.com/CALITHERA-BIOSCIENCES-IN-18126550/company/
Mr. Lampert is the founder and General Partner of BVF Partners L.P. (“BVF”), a San Francisco-based, private biotechnology investment firm established in 1993 that manages the Biotechnology Value Fund, L.P. and related entities. Mr. Lampert has been active in the biotechnology industry since 1984, having served on the boards of directors of numerous public and private companies. Prior to forming BVF, Mr. Lampert was a Vice President at the investment banking firm Oppenheimer & Co and the founder of Biotechnology Royalty Corp., aimed at pooling university biotechnology patent royalties. Mr. Lampert was previously employed by Cambridge NeuroScience, G.D. Searle & Co., and the Boston Consulting Group. He is a founding donor to the Lampert-Byrd Foundation and GiveDirectly.org. Born and raised in Ann Arbor, Michigan, Mr. Lampert holds an A.B. with honors in Chemistry from Harvard College and an M.B.A. from Harvard Business School
https://investforkidschicago.org/all-speakers/mark-lampert/
https://investforkidschicago.org/all-speakers/hank-paulson/
https://www.finviz.com/insidertrading.ashx?oc=1055947&tc=7&b=2
perfectly normal looking dude…./s cap #2